IP Library Granted Patent US 8,574,619
Granted Patent B2
US 8,574,619 · App. 12/205,070 · Granted Nov 5, 2013

Reducing cholesterol levels with combined use of quercetin and statin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,574,619
App. No.
12/205,070
Granted
Nov 5, 2013
Kind
B2
Abstract

A method of reducing the cholesterol level of a subject by administering to that subject quercetin, vitamin C, vitamin B3, and statin.

Claims (37)

1. A method of lowering the plasma cholesterol level of a subject, comprising administering to a subject in need thereof an effective amount of a first composition containing quercetin, resveratrol, vitamin C, and vitamin B3, and an effective amount of a second composition containing a statin, wherein the first composition has a weight ratio of 1:0.2-2.5:0.02-1 between quercetin, vitamin C, and vitamin B3.

2. The method of claim 1 , wherein the weight ratio is 1:0.5-1:0.02-0.2.

3. The method of claim 1 , wherein the weight ratio is 1:0.5-1:0.25-1.

4. The method of claim 2 , wherein the weight ratio is 1:1:0.04.

5. The method of claim 1 , wherein the effective amount of the first composition is an amount that provides 500 mg-1000 mg quercetin per day.

6. The method of claim 5 , wherein the effective amount of the first composition is an amount that provides 500 mg quercetin per day.

7. The method of claim 5 , wherein the effective amount of the first composition is an amount that provides 1000 mg quercetin per day.

8. The method of claim 1 , wherein the statin is atorvastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, lovastatin, provastatin, rosuvastatin, or simvastatin.

9. The method of claim 8 , wherein the statin is atorvastatin.

10. The method of claim 9 , wherein the effective amount of the second composition is an amount that provides atorvastatin at 10-20 mg per day.

11. The method of claim 1 , wherein the first composition further contains folic acid.

12. The method of claim 11 , wherein the first composition has a weight ratio of 1:0.2-2.5:0.02-1:0.2-2 (mg/mg/mg/mcg) between quercetin, vitamin C, vitamin B3, and folic acid.

13. The method of claim 12 , wherein the weight ratio is 1:0.5-1:0.02-0.2:0.5-1 (mg/mg/mg/mcg).

14. The method of claim 12 , wherein the weight ratio is 1:0.5-1:0.25-1:0.5-1 (mg/mg/mg/mcg).

15. The method of claim 13 , wherein the weight ratio is 1:1:0.04:0.8 (mg/mg/mg/mcg).

16. The method of claim 11 , wherein the effective amount of the first composition is an amount that provides 500-1000 mg quercetin 10-1000 mg resveratrol, 500-1000 mg vitamin C, 20-40 mg vitamin B3, and 400-800 mcg folic acid per day.

17. The method of claim 16 , wherein the effective amount of the first composition is an amount that provides 500 mg quercetin 10 mg resveratrol, 500 mg vitamin C, 20 mg vitamin B3, and 400 mcg folic acid per day.

18. The method of claim 16 , wherein the effective amount of the first composition is an amount that provides 1000 mg quercetin, 1000 mg vitamin C, 40 mg vitamin B3, and 800 mcg folic acid.

19. The method of claim 11 , wherein the statin is atorvastatin, cerivastatin, fluvastatin, mevastatin, pitavastatin, lovastatin, provastatin, rosuvastatin, or simvastatin.

20. The method of claim 19 , wherein the statin is atorvastatin.

21. The method of claim 20 , wherein the effective amount of the second composition is an amount that provides atorvastatin at 10-20 mg per day.

22. The method of claim 1 , wherein the second composition further contains ezetimibe, colesevelam, fenofibrate, red rice yeast, or omega-3.

23. The method of claim 1 , wherein the statin is simvastatin and the second composition further contains ezetimibe.

24. The method of claim 23 , wherein the effective amount of the second composition is an amount that provides 10-80 mg simvastatin and ezetimibe in combination.

25. The method of claim 1 , wherein the statin is provastatin and the second composition further contains fenofibrate.

26. The method of claim 25 , wherein the effective amount of the second composition is an amount that provides 40 mg provastatin and 145 mg fenofibrate per day.

27. The method of claim 1 , wherein the statin is atorvastatin and the second composition further contains colesevelam, fenofibrate, and ezetimibe.

28. The method of claim 1 , wherein the statin is simvastatin and the second composition further contains ezetimibe.

29. The method of claim 28 , wherein the effective amount of the second composition is an amount that provides 10-40 mg simvastatin and ezetimibe in combination and 1000 mg vitamin B3 per day.

30. The method of claim 1 , wherein the statin is simvastatin and the second composition contains ezetimibe, and omega-3.

31. The method of claim 1 , wherein the first composition is in dry form.

32. The method of claim 1 , wherein the first composition is in liquid form.

33. The method of claim 1 , wherein the first composition is a food product.

34. The method of claim 33 , wherein the food product is tea, juice, milk, coffee, a soft drink, jelly, ice cream, yogurt, cereal, chocolate, a cookie, or a snack bar.

35. The method of claim 1 , wherein the first composition is a dietary supplement.

36. The method of claim 35 , wherein the first composition is in the form of a tablet, a capsule, a soft chew, or a gel.

37. The method of claim 11 , wherein the second composition further contains ezetimibe, colesevelam, fenofibrate, red rice yeast, or omega-3.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: QUERCEGEN PHARMA A.G.
To: LINES, THOMAS CHRISTIAN
Reel/Frame 052151/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: LINES, THOMAS CHRISTIAN
To: QUERCIS PHARMA A.G.
Reel/Frame 052153/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2020
From: LINES, THOMAS; QUERCEGEN PHARMA LLC; QUERCEGEN PHARMA LLP; QUERCEGEN TECHNOLOGIES; QUERCEGEN PHARMACEUTICALS, LLC; QUERCEGEN HOLDINGS, LLC; NEW SUN NUTRITION, LLC; THE FRS COMPANY
To: QUERCEGEN PHARMA, AG.
Reel/Frame 052110/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: LINES, THOMAS CHRISTIAN
To: QUERCEGEN PHARMACEUTICALS LLC
Reel/Frame 025506/0227 →